These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 25528466)

  • 1. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analytical approach to assess the predictive value of biomarkers in Phase II decision making.
    Nikolakopoulos S; van der Wal WM; Roes KC
    J Biopharm Stat; 2013; 23(5):1106-23. PubMed ID: 23957519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.
    Yu Z; Ramakrishnan V; Meinzer C
    J Biopharm Stat; 2019; 29(2):306-317. PubMed ID: 30763151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian estimate of the concordance correlation coefficient with skewed data.
    Feng D; Baumgartner R; Svetnik V
    Pharm Stat; 2015; 14(4):350-8. PubMed ID: 26033433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
    Renfro LA; Shi Q; Sargent DJ; Carlin BP
    Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust meta-analytic-predictive priors in clinical trials with historical control information.
    Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
    Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive probability of success using surrogate endpoints.
    Saint-Hilary G; Barboux V; Pannaux M; Gasparini M; Robert V; Mastrantonio G
    Stat Med; 2019 May; 38(10):1753-1774. PubMed ID: 30548627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: an example from a vertigo phase III study with longitudinal count data as primary endpoint.
    Adrion C; Mansmann U
    BMC Med Res Methodol; 2012 Sep; 12():137. PubMed ID: 22962944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring event times in early phase clinical trials: some practical issues.
    Thall PF; Wooten LH; Tannir NM
    Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian hierarchical model for dose-finding trial incorporating historical data.
    Han L; Deng Q; He Z; Fleischer F; Yu F
    J Biopharm Stat; 2024 Aug; 34(5):646-660. PubMed ID: 37676029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
    Odani M; Fukimbara S; Sato T
    Clin Trials; 2017 Apr; 14(2):192-200. PubMed ID: 28059578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
    Zaslavsky BG
    Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence synthesis from aggregate recurrent event data for clinical trial design and analysis.
    Holzhauer B; Wang C; Schmidli H
    Stat Med; 2018 Mar; 37(6):867-882. PubMed ID: 29152777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian approach for assessing noninferiority in a three-arm trial with binary endpoint.
    Ghosh S; Tiwari RC; Ghosh S
    Pharm Stat; 2018 Jul; 17(4):342-357. PubMed ID: 29473291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting analysis time in event-driven clinical trials with event-reporting lag.
    Wang J; Ke C; Jiang Q; Zhang C; Snapinn S
    Stat Med; 2012 Apr; 31(9):801-11. PubMed ID: 22344853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints.
    Van der Elst W; Molenberghs G; Alonso A
    Stat Med; 2016 Apr; 35(8):1281-98. PubMed ID: 26612787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian basket trial design using a calibrated Bayesian hierarchical model.
    Chu Y; Yuan Y
    Clin Trials; 2018 Apr; 15(2):149-158. PubMed ID: 29499621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.